Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin
- PMID: 22334239
- DOI: 10.1038/ja.2012.7
Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin
Abstract
Antibiotic activity can differ depending on whether the bacterial target is extracellular or intracellular. To determine extracellular and intracellular activities of sitafloxacin (STX) against Staphylococcus aureus in comparison with levofloxacin (LVX) and moxifloxacin (MXF) in vivo and in vitro, three S. aureus strains (ATCC25923, 29213, 43300) were evaluated. MIC, MBC and mutant prevention concentration (MPC) of the test quinolone for S. aureus were determined by microdilution in broth, and intracellular activity was determined in RAW264.7 cells after phagocytosis of bacteria. Cellular quinolone accumulation was determined by HPLC. The time- and concentration-kill relationships were examined in vitro (in broth and in RAW264.7 cells, respectively) and in vivo by use of a mouse peritonitis model. The results showed that the activity of STX in broth cultures, including the MIC, MBC, MPC and the time- and concentration-kill relationships, were greater for STX than those for LVX and MXF. In particular, STX exhibited the strongest activity against intramacrophage S. aureus. The intracellular effects could be ranked in the following order as the mean change in the log10 number of cfu ml(-1) (log10 cfu ml(-1)) between treated and untreated mice: STX>LVX>MXF. It also showed that the dominant factor of intracellular activity in vivo was the frequency of doses. There was a poor correlation between the intracellular accumulation of the three different quinolones and the actual intracellular effect. The results of the intracellular and extracellular time- and concentration-kill relationships indicated that STX has the potential to display useful activity against extracellular and intracellular S. aureus.
Similar articles
-
Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.J Antimicrob Chemother. 2005 Apr;55(4):511-7. doi: 10.1093/jac/dki059. Epub 2005 Feb 24. J Antimicrob Chemother. 2005. PMID: 15731197
-
Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.J Antimicrob Chemother. 2007 Apr;59(4):755-8. doi: 10.1093/jac/dkm004. Epub 2007 Mar 12. J Antimicrob Chemother. 2007. PMID: 17353222
-
Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.Int J Antimicrob Agents. 2011 Apr;37(4):296-301. doi: 10.1016/j.ijantimicag.2010.12.014. Epub 2011 Feb 25. Int J Antimicrob Agents. 2011. PMID: 21353489
-
[Rhinosinusitis: etiopathogenesis and antimicrobial therapy, an update].Acta Otorhinolaryngol Ital. 2006 Feb;26(1 Suppl 82):5-22. Acta Otorhinolaryngol Ital. 2006. PMID: 16752855 Review. Italian.
-
Antibacterial Mechanisms and Clinical Impact of Sitafloxacin.Pharmaceuticals (Basel). 2024 Nov 16;17(11):1537. doi: 10.3390/ph17111537. Pharmaceuticals (Basel). 2024. PMID: 39598446 Free PMC article. Review.
Cited by
-
Osteogenic and Antibacterial Response of Levofloxacin-Loaded Mesoporous Nanoparticles Functionalized with N-Acetylcysteine.Pharmaceutics. 2025 Apr 15;17(4):519. doi: 10.3390/pharmaceutics17040519. Pharmaceutics. 2025. PMID: 40284514 Free PMC article.
-
Exosome-encapsulated antibiotic against intracellular infections of methicillin-resistant Staphylococcus aureus.Int J Nanomedicine. 2018 Nov 29;13:8095-8104. doi: 10.2147/IJN.S179380. eCollection 2018. Int J Nanomedicine. 2018. PMID: 30555228 Free PMC article.
-
Enhancing the antimicrobial activity of natural extraction using the synthetic ultrasmall metal nanoparticles.Sci Rep. 2015 Jun 5;5:11033. doi: 10.1038/srep11033. Sci Rep. 2015. PMID: 26046938 Free PMC article.
-
Establishing Sitafloxacin Epidemiological Cut-off Values (ECOFFs) for Clinical Bacterial Isolates.Infect Drug Resist. 2025 Apr 23;18:1993-2004. doi: 10.2147/IDR.S501783. eCollection 2025. Infect Drug Resist. 2025. PMID: 40290404 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases